Urs C. Schmidt-Ott to Recombinant Fusion Proteins
This is a "connection" page, showing publications Urs C. Schmidt-Ott has written about Recombinant Fusion Proteins.
Connection Strength
0.319
-
Evaluation of Physician Knowledge of Safety and Safe Use Information for Intravitreal Aflibercept Injection in Europe: A Second Survey of Physicians Following Dissemination of Updated Risk-Minimization Materials. Pharmaceut Med. 2024 Jan; 38(1):63-73.
Score: 0.206
-
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23; 403(10432):1141-1152.
Score: 0.052
-
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial. Lancet. 2024 Mar 23; 403(10432):1153-1163.
Score: 0.052
-
RNA binding and translational suppression by bicoid. Nature. 1996 Feb 22; 379(6567):746-9.
Score: 0.008